• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Emergent Biosolutions Inc. (Amendment)

    1/18/24 4:16:22 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EBS alert in real time by email
    SC 13G/A 1 EBS_SC13GA1.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    (AMENDMENT NO. 1)

    EMERGENT BIOSOLUTIONS INC.
    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.001 PER SHARE
    (Title of Class of Securities)

    29089Q105
    (CUSIP Number)

    DECEMBER 31, 2023
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    29089Q105

    SCHEDULE 13G

    Page  
    2
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     2,095,662
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     2,095,662
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,095,662
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.0%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    29089Q105

    SCHEDULE 13G

    Page  
    3
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     2,095,662
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     2,095,662
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,095,662
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.0%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    29089Q105

    SCHEDULE 13G

    Page  
    4
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     2,095,662
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     2,095,662
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,095,662
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.0%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    29089Q105

     SCHEDULE 13G

    Page  
    5
      of   
    10
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      Emergent BioSolutions Inc.
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    400 Professional Drive, Suite 400
    Gaithersburg, Maryland 20879

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    common stock, par value $0.001 per share ("Common Stock")
     
      (e) CUSIP Number:
    29089Q105
     
     

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    29089Q105

     SCHEDULE 13G

    Page  
    6
      of   
    10
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned:

       See response to Item 9 on each cover page.

    (b) Percent of Class:   

       See response to Item 11 on each cover page.

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       See response to Item 5 on each cover page.


                         
    CUSIP No.
     
    29089Q105

     SCHEDULE 13G

    Page  
    7
      of   
    10

    (ii) Shared power to vote or to direct the vote

       See response to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of

       See response to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of

       See response to Item 8 on each cover page.

       The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    29089Q105

    SCHEDULE 13G

    Page  
    8
      of   
    10

    Exhibits:

    Exhibit I:  Joint Filing Agreement, dated as of January 17, 2024, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    29089Q105

    SCHEDULE 13G

    Page  
    9
      of   
    10
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: January 17, 2024

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    29089Q105

    SCHEDULE 13G

    Page  
    10
      of   
    10
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.001 per share, of Emergent BioSolutions Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: January 17, 2024

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $EBS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EBS

    DatePrice TargetRatingAnalyst
    12/30/2024$15.00Buy
    H.C. Wainwright
    8/22/2024$16.00Buy
    Rodman & Renshaw
    3/7/2024$5.00Hold → Buy
    The Benchmark Company
    11/20/2023Underweight
    JP Morgan
    8/29/2023Buy → Hold
    The Benchmark Company
    4/10/2023$22.00Hold → Buy
    The Benchmark Company
    3/17/2023$23.00 → $9.00Neutral → Underweight
    JP Morgan
    11/10/2022Buy → Hold
    The Benchmark Company
    More analyst ratings

    $EBS
    SEC Filings

    View All

    SEC Form EFFECT filed by Emergent BioSolutions Inc.

    EFFECT - Emergent BioSolutions Inc. (0001367644) (Filer)

    8/18/25 12:15:25 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Emergent BioSolutions Inc.

    144 - Emergent BioSolutions Inc. (0001367644) (Subject)

    8/15/25 4:04:54 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Emergent BioSolutions Inc.

    S-3 - Emergent BioSolutions Inc. (0001367644) (Filer)

    8/7/25 4:15:37 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target

    H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00

    12/30/24 7:24:57 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Emergent BioSolutions with a new price target

    Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00

    8/22/24 7:22:39 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00

    3/7/24 10:14:18 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Papa Joseph C bought $349,800 worth of shares (60,000 units at $5.83), increasing direct ownership by 21% to 342,500 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    5/15/25 4:02:40 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zoon Kathryn C sold $62,853 worth of shares (7,086 units at $8.87), decreasing direct ownership by 9% to 71,799 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    8/18/25 4:33:31 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Degolyer Donald W sold $67,831 worth of shares (7,844 units at $8.65), decreasing direct ownership by 5% to 137,659 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    8/13/25 4:22:58 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Bioservices Hartzel William covered exercise/tax liability with 4,263 shares, decreasing direct ownership by 4% to 103,692 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    7/15/25 4:04:10 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Emergent BioSolutions Reports Second Quarter 2025 Financial Results

    Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 millionSecond Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps, respectively, versus prior yearSecond Quarter 2025 Gross Margin % of 36% and Adjusted Gross Margin % of 49%, an expansion of 6,200 bps and 2,300 bps, respectively, versus prior yearSecond Quarter 2025 Adjusted EBITDA of $28.5 million, an increase of 382% versus prior yearSecond Quarter 2025 Adjusted EBITDA Margin of 20% of Total Revenues, an improvement of 2,400 bps versus prior yearRaising the low end/midpoint of Full Year 2025 Profitability Guidance GAITHERSBURG, Md., Aug. 06, 2025 (GLOBE NE

    8/6/25 4:15:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

    GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the publication of a comprehensive review article, "Brincidofovir in the Era of Mpox," in the peer-reviewed journal Expert Review of Anti-infective Therapy.1 This publication includes an overview of brincidofovir, in vitro and in vivo data, including human case studies of the investigational use of brincidofovir, the current evaluation for treating mpox infections in adults and pediatrics in the Democratic Republic of Congo, and the potential for combination therapy with tecovirimat for immunocompromised patients with severe disease.     "We believe in the importance of assessing bri

    7/28/25 8:50:38 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

    GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announces its recognition of the U.S. House of Representatives for adding over-the-counter (OTC) naloxone to every AED location in its buildings, providing direct access to first responders and anyone coming across an individual who may be experiencing an opioid overdose. This effort has been led by Representative Buddy Carter (R-GA), with his team and congressional constituents, who have kept this public health issue a priority. Expanding access to potentially life-saving treatments is critical to saving more Americans and their families from an opioid overdose death. Emergent remains focus

    7/28/25 8:50:22 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Leadership Updates

    Live Leadership Updates

    View All

    Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

    Executive Management Team appointments contribute to Emergent's transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical an

    11/4/24 7:30:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

    Ongoing support of the ‘White House Challenge to Save Lives from Overdose' through workplace and public safety measuresOne-year mark of Ready to Rescue public awareness campaign to expand awareness, particularly among young adults and vulnerable communities20,000 additional doses of NARCAN® Nasal Spray to be donated to organizations in need GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emerg

    10/8/24 5:32:28 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

    MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro

    9/4/24 8:00:00 AM ET
    $CADL
    $EBS
    $MIST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $EBS
    Financials

    Live finance-specific insights

    View All

    Emergent BioSolutions Reports Second Quarter 2025 Financial Results

    Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 millionSecond Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps, respectively, versus prior yearSecond Quarter 2025 Gross Margin % of 36% and Adjusted Gross Margin % of 49%, an expansion of 6,200 bps and 2,300 bps, respectively, versus prior yearSecond Quarter 2025 Adjusted EBITDA of $28.5 million, an increase of 382% versus prior yearSecond Quarter 2025 Adjusted EBITDA Margin of 20% of Total Revenues, an improvement of 2,400 bps versus prior yearRaising the low end/midpoint of Full Year 2025 Profitability Guidance GAITHERSBURG, Md., Aug. 06, 2025 (GLOBE NE

    8/6/25 4:15:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

    GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can be

    7/15/25 7:30:16 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Reports First Quarter 2025 Financial Results

    First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior yearFirst Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior yearFirst Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior yearReaffirmed FY 2025 Guidance GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 

    5/7/25 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Emergent BioSolutions Inc.

    SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)

    11/13/24 4:00:18 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

    SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    11/8/24 5:23:28 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

    SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    9/10/24 12:09:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care